We formulated the vaccine by incorporating the characterized antigenic peptides to pre-formed CaPNPs through physical adsorption. and -A24 binding DV serotypes conserved epitopes, and the feasibility of an epitope based vaccine for DV contamination. In this study, we build on those previous studies and describe an investigational DV vaccine using T cell epitopes incorporated into a calcium phosphate nanoparticle (CaPNP) delivery system. This study presents a comprehensive analysis of functional immunogenicity of DV CaPNP/multipeptide formulations and and demonstrates the CaPNP/multipeptide vaccine is usually capable of inducing T cell responses against all 4 serotypes of DV. This synthetic vaccine is also cost effective, straightforward to manufacture, and stable at room heat in a lyophilized form. This formulation may serve as an effective candidate DV vaccine that protects against all 4 serotypes as either a prophylactic or therapeutic vaccine. family and is usually characterized by a single stranded RNA genome enclosed MN-64 within a spherical enveloped virion. Four unique serotypes of DV circulate globally with most endemic countries reporting blood circulation of all 4 serotypes. 1 The incidence of DV infections has spread dramatically around the world in recent decades; although recent estimates indicate that roughly 390? million people are infected with DV each year,2 over 3?billion people are actually at risk of being infected.3 As the climate continues to warm and the mosquito vector of DV continues to move northward4,5 both the quantity of infections and the number of people at risk of contamination will continue to rise. Therefore, developing efficacious anti-viral treatments and/or vaccines to prevent contamination from these viruses is usually of the utmost importance. One of the most challenging aspects of DV immunotherapy is usually that although recovery from contamination by one DV serotype may provide lifelong immunity against that particular strain, cross-protective immunity to other serotypes is only partial and temporary. Subsequent infections by other serotypes increase the risk of developing severe dengue fever, or dengue hemorrhagic fever, mediated by antibody dependent enhancement (ADE) of contamination.6,7 This is compounded by the MN-64 fact that there are no specific anti-viral treatments of JAG2 DV infection. Clinical management of infection is based only on supportive therapy. Recent improvements in case management have reduced the fatality rates in hospitalized dengue illness MN-64 to less than 1%.8 Other primary forms of combating the virus have targeted the viral vector,9 though the data supporting positive impact on incidence of DV infection is limited.10 In terms of prophylactic measures, there is one live attenuated tetravalent dengue vaccine (CYD-TDV, or Dengvaxia) first approved for use in Mexico, Philippines and Brazil in 2015 and many other countries thereafter. CYD-TVD induces neutralizing antibodies against all 4 DV serotypes where induction of high-titer neutralizing antibodies can provide temporary cross-protection to these serotypes, lasting about 2 years.11,12 However, CYD-TVD shows some shortcomings. First, the efficacy of CYD-TVD for confirmed dengue cases was surprisingly lower in seronegative individuals than in seropositive individuals, 13 perhaps reflecting a improving phenomenon that temporality provides additional cross-protection. Furthermore, the rate of hospitalization of sero-negative individuals was considerably higher, especially among children more youthful than 9 years old.14 This observation was attributed to CYD-TDV inducing non-protective dengue antibodies that enhance infection.15 As such, there still remains a significant need to develop efficacious prophylactics and immunotherapies for DV infections. There are several variables important to developing a successful DV vaccine. Inducing both humoral and cellular immunity will be essential in forming a safe and effective cross-protective DV vaccine. Therefore it is necessary to use tools that identify conserved B-cell and T-cell epitopes within viral proteins that stimulate protective immune responses16 but not the immune MN-64 amplification17,18 observed during antibody mediated enhancement of DV contamination. T cell based vaccines are an attractive alternative strategy as they can be used as stand-alone vaccines or be paired with current and future anti-viral treatments and/or the CYD-TDV vaccine. CD8+ cytotoxic T lymphocytes (CTLs) are a major contributor of protection against DV contamination.6,7,19 DV specific CD8+ T cells were detected in patients after natural infection20-24 and after attempts at vaccination25 with some MN-64 level of cross-reactivity between the strains. Studies in children have indicated that CD8+ T cell mediated secretion of IFN- and TNF- was more robust in asymptomatic or subclinical infections compared with symptomatic or severe disease.16.